英国慢性髓性白血病患者真实世界酪氨酸激酶抑制剂治疗路径、监测模式及应答:UK TARGET CML研究
UK TARGET CML是一项回顾性观察研究,纳入2013至2017年间接受一线TKI治疗的257例慢性期CML患者,其中203例一线使用伊马替尼。尽管44%患者需至少一次更换TKI,但分子学评估常被遗漏,23%的ELN定义治疗失败患者未更换TKI,因耐药更换TKI者中仅49%进行了激酶域突变分析。一线伊马替尼者MMR和DMR分别为50%和29%,一线二代TKI者分别为63%和54%。
要点
- 44%患者需至少一次更换TKI,但23%的ELN定义治疗失败患者未更换TKI。
- 因耐药更换TKI的患者中仅49%进行了激酶域突变分析。
- 一线伊马替尼者MMR 50%、DMR 29%;一线二代TKI者MMR 63%、DMR 54%。
核心结论
- 真实世界CML管理中分子学评估常被遗漏,部分ELN定义治疗失败患者未更换TKI,因耐药更换TKI者突变分析比例低,心血管风险因素在TKI管理中考虑不足,提示CML诊疗有改进空间。
研究设计与样本
- UK TARGET CML为回顾性观察研究,纳入2013至2017年间接受一线TKI治疗的257例慢性期CML患者,其中203例一线使用伊马替尼。
主要发现
- 44%患者需至少一次更换TKI,23%的ELN定义治疗失败患者未更换TKI,因耐药更换TKI者中仅49%进行了激酶域突变分析。
- 一线伊马替尼患者中MMR(BCR-ABL1IS ≤0.1%)为50%、DMR(BCR-ABL1IS ≤0.01%)为29%。
- 一线二代TKI患者中MMR为63%、DMR为54%。
- 随访≥13个月可评估的二线二代TKI患者中MMR为77%、DMR为44%。
- 鲜有证据表明TKI管理过程中考虑了心血管风险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real-world CML management is consistent with these goals. We report results of UK TARGET CML, a retrospective observational study of 257 patients with chronic-phase CML who had been prescribed a first-line TKI between 2013 and 2017, most of whom received first-line imatinib (n = 203). Although 44% of patients required ≥1 change of TKI, these real-world data revealed that molecular assessments were frequently missed, 23% of patients with ELN-defined treatment failure did not switch TKI, and kinase domain mutation analysis was performed in only 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR-ABL1IS ≤0·1%) and deep molecular response (DMR; BCR-ABL1IS ≤0·01%) were observed in 50% and 29%, respectively, of patients treated with first-line imatinib, and 63% and 54%, respectively, receiving a second-generation TKI first line. MMR and DMR were also observed in 77% and 44% of evaluable patients with ≥13 months follow-up, receiving a second-generation TKI second line. We found little evidence that cardiovascular risk factors were considered during TKI management. These findings highlight key areas for improvement in providing optimal care to patients with CML.
引用
- Milojkovic D, Cross NCP, Ali S, et al. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. Br J Haematol. 2020. PMID: 32449159. doi:10.1111/bjh.16733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。